Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2013

View Archived Issues

Royalty Pharma makes firm offer to acquire Elan

Association between rs17587 polymorphism of the PSMB9 gene and RA

Pfenex and Agila Biotech form joint venture to develop biosimilar products

Genentech presents data for novel PI3K inhibitors

Stem Cell Therapeutics licenses rights to cancer stem cell program

GPR40 agonist shows improved pharmacokinetics and selectivity

BioLineRx phase IIa study in ulcerative colitis meets primary endpoint

CanBas reports topline results from phase II trial of CBP-501 in NSCLC

Novel radioligands developed for 5-HT4 receptor imaging

PharmAthene's rBChE shown to bind to broad spectrum of nerve agents

Researchers from Ontario identify miR-605 as a novel genetic modifier in LFS

Tekmira presents preliminary phase I results for TKM-080301

Adelaide Research and Innovation presents new pneumococcal vaccines

IgenMed Pharmaceuticals presents novel fusion proteins

New bispecific antibodies divulged by Amgen

Merck & Co. discloses novel aldosterone synthase inhibitors

FDA clears SKL-15508 IND

ARMGO Pharma receives MDA support to advance novel DMD drug

Phase II trial of AeroVanc begins for MRSA lung infection in patients with cystic fibrosis

Resverlogix completes dosing in phase IIb ASSURE trial

Pluristem Therapeutics expands PLX pipeline in orthopedics and sports medicine

Targacept completes recruitment in phase IIb trial of TC-5619

Addex Therapeutics reports preclinical data for dipraglurant

Interprotein and Takeda sign new molecular design agreement

SK Biopharmaceuticals and SK Chemicals establish alliance for YKP-10811

Shin Nippon Biomedical and Besins Healthcare sign nasal drug delivery agreement

Pharmacyclics updates progression of ibrutinib trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...